Screener
MapLight Therapeutics, Inc. MPLT Employee Related — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:25 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224129
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Clinical trial expenses | $24,819 | $1,939 |
| Employee-related research and development expenses | 15,993 | 7,050 |
| Chemistry, manufacturing and controls expenses | 6,417 | 3,956 |
| Preclinical program expenses | 5,522 | 6,081 |
| Other research and development expenses | 933 | 761 |
| Employee-related general and administrative expenses | 6,990 | 2,060 |
| Professional fees and other general and administrative expenses | 3,829 | 1,696 |
| Other segment items(1) | (3,835) | (1,203) |
Item 1. Financial Statements.
FAQ
- What is MapLight Therapeutics, Inc.'s employee related — research and development expense?
- MapLight Therapeutics, Inc. (MPLT) reported employee related — research and development expense of $15.99M in Q1 2026.
- How has MapLight Therapeutics, Inc.'s employee related — research and development expense changed year-over-year?
- MapLight Therapeutics, Inc.'s employee related — research and development expense increased by 126.9% year-over-year, from $7.05M to $15.99M.
- What does employee related — research and development expense mean?
- This metric represents the portion of total research and development expenditures specifically allocated to personnel costs, including salaries, benefits, and stock-based compensation for scientific and clinical staff. It reflects the company's investment in human capital required to advance its drug pipeline and clinical trial programs. Monitoring this figure helps investors assess the company's commitment to internal innovation and the scalability of its clinical development operations.
Ask your AI about MapLight Therapeutics, Inc.'s employee related — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude